Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H26O2 |
| Molecular Weight | 286.4085 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O
InChI
InChIKey=AEMFNILZOJDQLW-QAGGRKNESA-N
InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1
| Molecular Formula | C19H26O2 |
| Molecular Weight | 286.4085 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB01536Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18203558 | https://www.ncbi.nlm.nih.gov/pubmed/8476772 | https://www.ncbi.nlm.nih.gov/pubmed/27558186
Sources: https://www.drugbank.ca/drugs/DB01536
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18203558 | https://www.ncbi.nlm.nih.gov/pubmed/8476772 | https://www.ncbi.nlm.nih.gov/pubmed/27558186
Androstenedione (Δ4-Androstenedione, 4-androstene-3,17-dione or 17-ketotestosterone) is an endogenous androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA). In turn, Androstenedione is also a precursor of dihydrotestosterone (DHT), estrogens such as estradiol and estrone, and the neurosteroid 3α-androstanediol. Androstenedione is used to increase the production of the hormone testosterone to enhance athletic performance, increase energy, keep red blood cells healthy, enhance recovery and growth from exercise, and increase sexual desire and performance. Androstenedione has been shown to increase serum testosterone levels over an eight-hour period in men when taken as a single oral dose of 300 mg per day, but a dose of 100 mg had no significant effect on serum testosterone. However, serum levels of estradiol increased following both the 100 mg and 300 mg doses. The study also reported that the serum level of estrogens and testosterone produced varied widely among individuals. Androstenedione is currently used as a nutritional supplement to grow bigger muscles and stronger bones. This implies that androstenedione may have anabolic properties. Even though it has not been convincingly demonstrated yet that androstenedione is an anabolic steroid, its anabolic properties are likely based on its proven ability to increase testosterone levels. The role of testosterone in building stronger muscles and bones is widely accepted. Thus, high doses of testosterone-boosting drugs combined with strength training have been shown to increase muscle size and strength even in normal young men. This confirms what thousands of athletes who take anabolic steroids have known for decades. Yet androstenedione is different from testosterone-boosting drugs in a number of important aspects. To begin with, androstenedione is a naturally occurring substance that is produced by the body itself. In contrast to synthetic anabolic steroids, androstenedione is right at home in the human body, and perfectly complements the complex hormonal network in the body. Information about possible side effects and risks of androstenedione is very limited. Also, recent studies show that the drug's actions don't support manufacturer's claims. While a few individuals have shown increased levels of testosterone, most failed to achieve increases in blood testosterone levels. Initial medical research has raised concerns about this supplement's safety. Doctors worry that androstenedione may increase the risk of heart disease or liver cancer. In addition, research also associates androstenedione use with increases in estradiol, a female estrogen.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11806715 |
489.0 nM [IC50] | ||
Target ID: CHEMBL1978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22444875 |
30.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Detection and determination of anabolic steroids in nutritional supplements. | 2001-07 |
|
| Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens. | 2001-07 |
|
| The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. | 2001-06 |
|
| Decline in circulating estradiol during the periovulatory period is correlated with decreases in estradiol and androgen, and in messenger RNA for p450 aromatase and p450 17alpha-hydroxylase, in bovine preovulatory follicles. | 2001-06 |
|
| Aromatase inhibition by an 11,13-dihydroderivative of a sesquiterpene lactone. | 2001-06 |
|
| Leukemia inhibitory factor antagonizes gonadotropin induced-testosterone synthesis in cultured porcine leydig cells: sites of action. | 2001-06 |
|
| Biotransformation of cholesterol using Lactobacillus bulgaricus in a glucose-controlled bioreactor. | 2001-06 |
|
| Importance of amino acid residue 474 for substrate specificity of canine and human cytochrome p450 3A enzymes. | 2001-05-15 |
|
| Over-the-counter drug use in gymnasiums: an underrecognized substance abuse problem? | 2001-05-08 |
|
| Serum hormones and the alcohol-breast cancer association in postmenopausal women. | 2001-05-02 |
|
| Effects of thyroid hormones on bovine granulosa and thecal cell function in vitro: dependence on insulin and gonadotropins. | 2001-05 |
|
| Gas chromatography-mass spectrometric determination of activity of human placental aromatase using 16alpha-hydroxyandrostenedione as a substrate. | 2001-05 |
|
| Sebocytes are the key regulators of androgen homeostasis in human skin. | 2001-05 |
|
| Regulation of glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? | 2001-05 |
|
| The role of the liver in the acute effect of alcohol on androgens in women. | 2001-05 |
|
| Role of the follistatin gene in women with polycystic ovary syndrome. | 2001-05 |
|
| Dynamics of bioactive follicle-stimulating hormone secretion in women with polycystic ovary syndrome: effects of estradiol and progesterone. | 2001-05 |
|
| Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? | 2001-05 |
|
| Virilization during pregnancy caused by ovarian mucinous cystadenocarcinoma. | 2001-05 |
|
| A conditional tetracycline-regulated increase in Gamma amino butyric acid production near luteinizing hormone-releasing hormone nerve terminals disrupts estrous cyclicity in the rat. | 2001-05 |
|
| Inhibin A is a follicle stimulating hormone-responsive marker of granulosa cell differentiation, which has both autocrine and paracrine actions in sheep. | 2001-05 |
|
| Expression and localization of cytochrome P450 17 alpha-hydroxylase/c17,20-lyase in the avian brain. | 2001-04-27 |
|
| Maternal androgens in black-headed gull (Larus ridibundus) eggs: consequences for chick development. | 2001-04-22 |
|
| Testicular development, histology, and hormone profiles in three yearling angus bulls with spermatogenic arrest. | 2001-04-15 |
|
| Leuprolide acetate treatment of adrenocortical disease in ferrets. | 2001-04-15 |
|
| Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits. | 2001-04-12 |
|
| Adrenal steroids in human prostatic cancer cell lines. | 2001-04-12 |
|
| Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow. | 2001-04 |
|
| Pharmacokinetics and metabolism of formestane in breast cancer patients. | 2001-04 |
|
| Aromatase inhibition reduces specifically one display of the ring dove courtship behavior. | 2001-04 |
|
| Sources of elevated serum androgens in postmenopausal women who develop breast cancer. | 2001-04 |
|
| 19-Oxygenation of C19-steroids with an A, B-ring enone structure, competitive inhibitors of estrogen biosynthesis, with human placental aromatase. | 2001-04 |
|
| Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. | 2001-04 |
|
| Novel assay for determination of androgen bioactivity in human serum. | 2001-04 |
|
| Candidate gene analysis in premature pubarche and adolescent hyperandrogenism. | 2001-04 |
|
| Serum and follicular fluid hormone levels during in vitro fertilization after short- or long-course treatment with a gonadotropin-releasing hormone agonist. | 2001-04 |
|
| Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). | 2001-04 |
|
| Developmental regulation of morphological differentiation of placental villous trophoblast in the baboon. | 2001-04 |
|
| Effect of beta-estradiol on voltage-gated Ca(2+) channels in rat hippocampal neurons: a comparison with dehydroepiandrosterone. | 2001-03-30 |
|
| Circulating plasma leptin and IGF-1 levels in girls with premature adrenarche: potential implications of a preliminary study. | 2001-03 |
|
| Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development, and therapeutic considerations. | 2001-03 |
|
| Assessment of endocrine status in patients undergoing in-vitro fertilization treatment. Is it necessary? | 2001-03 |
|
| Sex hormone-binding globulin as a marker of the effect of hormonal treatment in Turner's syndrome. | 2001-03 |
|
| Testosterone deficiency in women. | 2001-03 |
|
| Genomic organization of a human 5beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme. | 2001-01-26 |
|
| Morphometric analysis of cortical bone upon the exposure to sustained delivery of anabolic promoting agents using adult male rats as a model. | 2001 |
|
| Morphometric analysis of the adrenal compartments exposed to sustained delivery of androgens. | 2001 |
|
| Differential age-related changes of hypothalamus - pituitary - adrenal axis hormones in healthy women and men - role of interleukin 6. | 2001 |
|
| Effects of transdermal application of 7-oxo-DHEA on the levels of steroid hormones, gonadotropins and lipids in healthy men. | 2001 |
|
| Secretion from neuropeptide-treated splenocytes modifies ovarian steroidogenesis. | 2001 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27558186
In clinical study the experimental group consisted of 6 men (mean age±SE, 62.33±2.57) taking 300 mg of androstenedione supplement for 7 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8476772
Wild-type MCF-7 cell and MCF-7 cell sublines, one of which was stably transfected with the aromatase and neomycin resistance expression plasmids (MCF-7 CA) and the other only with the neomycin resistance expression plasmid (MCF-7 Cc) were used for activity evaluation. 300nM [3H]androstenedione is added to flasks containing cells seeded at 40,000 cells/cm 2 and the percent conversion to estrone and estradiol determined. A total of 106dpm/flask soo of 7alpha-[3H]androstenedione (NEN/Dupont, Boston, MA) was used as the substrate and 400 [3H]estrone and [3H]estradiol purified using thin layer chromatography. Results from the aromatase assays are expressed as pmol of estrogen (estrone and estradiol) formed per mg of DNA during either 1 or 3 days of incubation of substrate with cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:35:48 GMT 2025
by
admin
on
Mon Mar 31 17:35:48 GMT 2025
|
| Record UNII |
409J2J96VR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
53343-0
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
15028-4
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LIVERTOX |
57
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
1853-1
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
53337-2
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
CFR |
21 CFR 862.1075
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
53336-4
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
1851-5
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
9319-5
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
DEA NO. |
4000
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
72489-8
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
53344-8
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
1855-6
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
14603-5
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
15027-6
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
34240-2
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
43817-6
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
9310-4
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
1854-9
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
34239-4
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
1852-3
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
||
|
LOINC |
35190-8
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C244
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
215
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
1646010
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL274826
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
ANDROSTENEDIONE
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
D000735
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
200-554-5
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
409J2J96VR
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
63-05-8
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
9563
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
m1901
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
784
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | RxNorm | ||
|
7335
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
6128
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
DTXSID8024523
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
DB01536
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
100000077419
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
16422
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
409J2J96VR
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY | |||
|
SUB12900MIG
Created by
admin on Mon Mar 31 17:35:48 GMT 2025 , Edited by admin on Mon Mar 31 17:35:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENZYME->SUBSTRATE |
Vmax
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|